LNC
IRD

Lincoln National Corp’s Opus Genetics IRD Stock Holding History

Lincoln National Corp’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,900
Closed -$23.9K – 1178
2024
Q1 		$23.9K Buy
11,900
+200
+2% +$507 ﹤0.01% 1194
2023
Q4 		$35.2K Hold
11,700
– – ﹤0.01% 1091
2023
Q3 		$39.2K Hold
11,700
– – ﹤0.01% 1014
2023
Q2 		$50.8K Buy
11,700
+100
+0.9% +$475 ﹤0.01% 1002
2023
Q1 		$43.5K Hold
11,600
– – ﹤0.01% 970
2022
Q4 		$40.9K Buy
+11,600
New +$30.5K ﹤0.01% 911

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Lincoln National Corp's IRD Position: Q2 2024 in Review

Lincoln National Corp sold out of Opus Genetics (IRD) in Q2 2024, closing a stake of 11,900 shares — an estimated $23.9K sold.

Lincoln National Corp first reported a position in IRD in Q4 2022 and held it in 6 quarters. The position peaked at $50.8K in Q2 2023. 37 funds tracked by Wall St. Rank hold IRD as of Q2 2024.

  • Lincoln National Corp reported no remaining Opus Genetics position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 11,900 Opus Genetics shares in Q2 2024, an estimated $23.9K.
  • Lincoln National Corp first reported a position in Opus Genetics in Q4 2022 and held it in 6 quarters.
  • Lincoln National Corp's Opus Genetics position peaked at $50.8K in Q2 2023.
  • 37 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.